Investigating the role of serotonin-2B receptors in heart disease
Serotonin-2B receptor in hypertrophic cardiomyopathy
This study is looking at how certain receptors in the heart might play a role in a serious heart condition called hypertrophic cardiomyopathy (HCM), which can be dangerous for young adults, and it aims to find new ways to help reduce heart scarring and improve heart health.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-11001126 on NIH RePORTER |
What this research studies
This research focuses on understanding how serotonin-2B receptors contribute to fibrosis in hypertrophic cardiomyopathy (HCM), a serious heart condition that can lead to sudden death in young adults. The study aims to explore the cellular mechanisms involved and assess the potential of targeting these receptors to reduce fibrosis, which is a key factor in the disease's progression. By using mouse models and analyzing cardiac fibroblasts, the researchers hope to identify new therapeutic strategies that could improve heart function and patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with hypertrophic cardiomyopathy, particularly young adults at risk of sudden cardiac events.
Not a fit: Patients with other forms of heart disease or those without a diagnosis of hypertrophic cardiomyopathy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that reduce heart fibrosis and improve the quality of life for patients with hypertrophic cardiomyopathy.
How similar studies have performed: Previous studies have shown promising results in reducing fibrosis through serotonin-2B receptor antagonism in related cardiac conditions, indicating a potential for success in this approach.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Livingston, William Bryan — Vanderbilt University
- Study coordinator: Livingston, William Bryan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.